MOG and myeloid sarcoma: The development of new techniques such as cell-based assay (CBA) and also the use of new proposed diagnostic classifications of inflammatory disorders, positive MOG-IgG patients may belong to a new clinical entity, distinct from MS and NMOSD (134, 135).